Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a single-center real-world study
S. Ren (Changsha, China), L. Yang (Changsha, China), Z. Tong (Changsha, China), R. Wang (Changsha, China), W. Han (Changsha, China), F. Yu (Changsha, China), W. Liu (Changsha, China), Y. Hu (Changsha, China)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ren (Changsha, China), L. Yang (Changsha, China), Z. Tong (Changsha, China), R. Wang (Changsha, China), W. Han (Changsha, China), F. Yu (Changsha, China), W. Liu (Changsha, China), Y. Hu (Changsha, China). Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a single-center real-world study. 1927
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|